生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于,试验药物Efzofitimod(剂量为5.0毫克/公斤)及其对照安慰剂的给药频率,将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现,为后续的临床开发与潜在上市申请收集关键数据。
生物制药公司aTyr Pharma Inc. 已公布其下一阶段三期临床试验方案的调整细节。核心变动在于,试验药物Efzofitimod(剂量为5.0毫克/公斤)及其对照安慰剂的给药频率,将从原有方案增加至每三周进行一次。这一调整旨在进一步评估该药物在延长给药间隔下的疗效与安全性表现,为后续的临床开发与潜在上市申请收集关键数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.